Cargando…
Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. However, studies regarding Crizotinib in pancreatic cancer have been limited. Thus, we investigated the effect of Crizotinib on pancreatic cancer and its mechanism of action. Crizotinib strongly suppre...
Autores principales: | Yan, Hong Hua, Jung, Kyung Hee, Son, Mi Kwon, Fang, Zhenghuan, Kim, Soo Jung, Ryu, Ye-Lim, Kim, Juyoung, Kim, Mi-Hyun, Hong, Soon-Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253425/ https://www.ncbi.nlm.nih.gov/pubmed/25193856 |
Ejemplares similares
-
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer
por: Rumman, Marufa, et al.
Publicado: (2016) -
Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer
por: Park, Jung Hee, et al.
Publicado: (2017) -
Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022) -
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018) -
Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)